Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Common Equity (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Common Equity for 13 consecutive years, with $232.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 25.33% to $232.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $232.7 million, a 25.33% increase, with the full-year FY2024 number at $175.5 million, changed N/A from a year prior.
  • Common Equity was $232.7 million for Q3 2025 at Theravance Biopharma, up from $224.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $480.6 million in Q3 2022 to a low of -$373.2 million in Q1 2021.
  • A 5-year average of $88.5 million and a median of $193.7 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: crashed 136.31% in 2021, then skyrocketed 248.51% in 2022.
  • Theravance Biopharma's Common Equity stood at -$323.6 million in 2021, then soared by 236.53% to $441.8 million in 2022, then plummeted by 44.29% to $246.1 million in 2023, then dropped by 28.68% to $175.5 million in 2024, then soared by 32.55% to $232.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Common Equity are $232.7 million (Q3 2025), $224.8 million (Q2 2025), and $166.0 million (Q1 2025).